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A B S T R A C T
Therapeutic hypothermia (32°C-34°C) is the only therapy that improved neurological 
outcome after cardiac arrest in randomized, controlled trials. It protects the brain af-
ter ischemia by reduction of brain metabolism, attenuation of reactive oxygen species 
formation, inhibition of excitatory amino acid release, attenuation of the immune re-
sponse during reperfusion and inhibition of apoptosis. Its use is recommended by the 
American Heart Association and the International Liaison Committee on Resuscita-
tion in unconscious adult patients for 12 to 24 hours following resuscitation from out-
of-hospital ventricular fibrillation cardiac arrest. The role of therapeutic hypothermia 
is uncertain when the initial cardiac rhythm is asystole or pulseless electrical activity, 
or when the cardiac arrest is primarily due to a noncardiac cause such as asphyxia or 
drug overdose. The possible neuroprotective effect of hypothermia following resus-
citation from non ventricular fibrillation cardiac arrest needs to be balanced against 
the associated cardiovascular, coagulation, immune, and electrolyte disturbances. 
Mild hypothermia is generally a safe and effective therapy after cardiac arrest, even 
in hemodynamically compromised patients and in patients undergoing percutaneous 
coronary intervention. Because the induction of therapeutic hypothermia has become 
more feasible with the development of simple intravenous cooling techniques and spe-
cialized equipment for improved temperature control in the intensive care unit, it is 
expected that therapeutic hypothermia will become more widely used in the manage-
ment of anoxic neurological injury whatever the presenting cardiac rhythm.
T H E  C L I N I C A L  P R O B L E M
About 450,000 Americans have cardiac arrest annually.1 About 80% of cardiac 
arrests occur at home, for which the rate of death is at least 90%.1,2 More than half 
the survivors have permanent brain damage of varying degrees.3,4 In–hospital arrests 
have better outcomes than those that occur outside the hospital, with restoration of 
circulation exceeding 50% and survival to hospital discharge reaching approximately 
20%.5,6
Cardiac arrest causes immediate cessation of cerebral blood flow and the subse-
quent oxygen deprivation leads to neurological ischemic injury after several minutes. 
If resuscitation results in restoration of spontaneous circulation (ROSC), an additional 
reperfusion injury occurs. The causes of the anoxia and reperfusion injury are complex 
and multifactorial but largely relate to metabolic disturbances that exacerbate cellular 
injury.7-18 Permanent neurological injury occurs after 5 to 10 minutes of complete ces-
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sation of cerebral blood flow at normothermia. There has been 
considerable research into treatments that may ameliorate this 
anoxic neurological injury. Although a number of drugs that 
inhibit the metabolic disturbances have produced encouraging 
results in animal models,11-17 their clinical efficacy still remains 
to be shown. At present, the only treatment with both labora-
tory and clinical supportive data in this setting is therapeutic 
hypothermia.11,12,18,19
T H E  R O L E  O F  H y P O T H E R M I A , 
M E C H A N I S M S  O F  N E U R O P R O T E C T I O N
Therapeutic hypothermia (TH) is defined as the controlled 
lowering of core body temperature to 32°C to 34°C.20 This tem-
perature goal represents the optimal balance between clinical 
effect and cardiovascular toxicity. In addition this temperature 
spectrum provides easier clinical management of shivering, 
one of the more severe complications of hypothermia, which 
may require substantial amounts of sedation or neuromuscular 
blockade to be suppressed.18 Cardiac arrhythmias generally 
occur at 31°C (e.g. slow atrial fibrillation), whereas at 28°C, 
spontaneous ventricular fibrillation (VF) may ensue.
Protective mechanisms of hypothermia include reduction 
of brain metabolism (metabolism is reduced by 5% to 8% per 
degree Celsius reduction of core temperature), attenuation 
of reactive oxygen species formation, inhibition of excitatory 
amino acid release, attenuation of the immune response dur-
ing reperfusion, inhibition of apoptosis, and modulation of 
nuclear factor kappa B expression.21,22
C O O L I N G  M E T H O d S
One of the major barriers in the past to the extension of TH 
has been the feasibility of this treatment. Nowadays numerous 
cooling methods are available, differing greatly in effective-
ness, controllability, invasiveness, and cost. Surface cooling 
devices are noninvasive and include simple ice packs, alcohol 
bathing, convective air blankets, and heat exchanger or water 
matresses.21,23-25 Ice packs applied to head, neck, torso, and 
extremities of the patient provide a relatively slow cooling rate 
of 0.9°C per hour.26 Although this technique is inexpensive, 
the application of ice packs is cumbersome.21 Invasive cooling 
methods include the administration of ice-cold fluids intra-
venously, intravascular cooling catheters, body cavity lavage, 
extracorporeal circuits, and selective brain cooling.21,27-31 The 
infusion of ice-cold fluids has the advantages of low price and 
ubiquitous availability, but require large infusion volumes. 21 
Factors that might influence the effectiveness of cooling with 
cold fluids are infusion speed and muscle relaxation. The use 
of an endovascular cooling catheter is limited to the hospital 
setting. The heat exchanger mattress and endovascular cooling 
catheters are also expensive, and the latter require insertion by 
a physician with additional training. Continuous temperature 
monitoring in patients receiving therapeutic hypothermia is 
as important as monitoring of arterial blood pressure during 
vasopressor therapy.25,26 Passive and slow rewarming is also 
recommendable.25 For the intensive care setting, we would 
recommend the endovascular cooling catheter technique,21,27 
in conjunction with continuous monitor display of bladder 
temperature.25 Cooling catheters can achieve whole body 
cooling rates of 1.5 °C per hour. Based on prior randomized 
controlled trial results,25 we would suggest maintenance 
of bladder temperature within 32°C to 34°C for at least 24 
hours, followed by a passive rewarming period of at least 12 
hours. For the emergency department, operating room, and/or 
hospital ward setting, we would suggest the placement of ice 
packs around the head, neck, torso, and limbs.26 This would 
enable the rapid initiation of cooling until the placement of 
the cooling catheter in the intensive care unit.
C L I N I C A L  d A T A
Therapeutic hypothermia has been in use for centuries.32 
In Figure 1, the so-called “Russian Method of Resuscitation” 
(1803) consisted of burying the victim of a cardiac arrest in 
snow33 (Figure 1).
More than two hundred years later (2005 guidelines), the 
American Heart Association and the European Resuscitation 
Council recommended the implementation of mild hypother-
mia in the post cardiac arrest treatment algorithm of patients 
140
HOSPITAL CHRONICLES 5(3), 2010
(12-24 hours following resuscitation), when the first document-
ed rhythm was VF or pulseless ventricular tachycardia, and 
state that hypothermia should be considered for the treatment 
of non-VF rhythms as well.34,35 The 2005 guidelines were based 
on two pivotal randomized, controlled trials.25,26 The first of 
these pivotal studies was a large, multicenter randomized, 
controlled
 
trial that enrolled 275 patients in 9 European hos-
pitals.25 Patients who were resuscitated from cardiac arrest 
with an initial cardiac rhythm of VF and transported to the 
hospital were eligible for participation to the study. Patients 
allocated to therapeutic hypothermia were cooled after arrival 
at the hospital using a mattress delivering cold air over the 
entire body, and cooling from 32°C to 34°C was maintained 
for 24 hours, followed by slow rewarming over 12 hours. In 
the therapeutic hypothermia group, 75 of 136 patients (55%) 
had a favorable neurological outcome (i.e. Pittsburgh Cerebral 
Performance Category 1 or 2), as compared with 54 of 137 
(39%) in the normothermia group (P=0.009). Mortality at 
6 months was 41% in the hypothermia group compared with 
55% in the normothermia group (P=0.02). The complications 
did not differ significantly between the two groups. Impor-
tantly, this trial excluded patients with a presenting rhythm 
other than VF, older patients (age 75 yrs or more), patients 
with hypotension (mean arterial pressure 60 mm Hg for more 
than 30 minutes after ROSC), and patients with hypoxia 
(arterial oxygen saturation 85% for 15 minutes after ROSC). 
The second randomized trial was conducted in 4 hospitals 
in Victoria, Australia.26 There were 77 patients allocated to 
either hypothermia
 
(33°C for 12 hours) or normothermia. The 
primary outcome measure was survival to hospital discharge 
with sufficiently good neurological function to be sent home 
or to a rehabilitation facility. Twenty-one of the 43 patients 
treated with hypothermia (49%) had a favorable outcome 
compared with 9 of the 34 (26%) treated with normothermia. 
After adjustment for small baseline differences in age and time 
from collapse to the ROSC, the odds ratio for a good outcome 
with hypothermia as compared with normothermia was 5.25 
(95% confidence interval=1.47-18.76; P=0.011). This study 
also enrolled only patients with VF as the presenting cardiac 
rhythm and stable hemodynamics, but did not exclude older 
patients or those with hypoxia.
Sagalyn et al,36 reviewed findings from recent literature 
on the post-resuscitation care of cardiac arrest patients hav-
ing undergone therapeutic hypothermia as part of non-trial 
treatment. An electronic search of the literature (PubMed; Na-
tional Library of Medicine, Washington, DC) was conducted 
to identify potential reports of therapeutic hypothermia after 
cardiac arrest. The search was conducted in November 2007 
and included papers in all languages. Studies were considered 
for analysis if they evaluated adult victims of sudden cardiac 
arrest (>18 years old), if they were not randomized controlled 
trials, and if they were published after 2002, i.e. the year of 
publication of the Bernard26 and HACA group25 trials. Stud-
ies with and without historical controls (non-hypothermia 
subjects) were included. All studies with historical controls 
included comparisons of survival (Table 1) and of survival 
with good neurological outcome (Table 2) between the former 
and therapeutic hypothermia-treated patients. Confirming the 
rate of survival improvement reported by the randomized tri-
als, the odds ratio reported in each study reflects the marked 
mortality benefit of therapeutic hypothermia, as well as the 
associated improvement in neurological recovery. Summary 
odds ratios are shown at the bottom lines of Tables 1 and 2 
and demonstrate an approximately two- to three-fold im-
provement in both survival and good neurological recovery 
when therapeutic hypothermia was applied. The survival and 
favorable neurological outcome data for the studies that did 
not
 
include historical controls are shown in Table 3. Despite 
this limitation, it is noteworthy that the overall survival to 
hospital discharge was 59%, which is similar to the 65% overall 
survival of the controlled studies cited in Table 1. In addition, 
the percentage of favorable neurological outcome in the stud-
TABLE 1. Survival in study subset with historical controls36
Author
n Historical control  
n (%)α
Therapeutic Hypothermia  
n (%) OR 95% CI HC TH
Arrich et al37  123 462 39 (32) 267 (58) 2. 9 1. 9-4. 6
Belliard et al38  36 32 13 (36) 18 (56) 2. 3 0. 8-6. 8
Busch et al39  34 27 11 (32) 16 (59) 3. 0 0. 9-9. 9
Oddo et al40  54 55 20 (37) 28 (51) 1. 8 0. 8-3. 8
Schefold et al41  31 31 21 (70) 21 (70) 1. 0 0. 3-2. 9
Sunde et al42  58 61 18 (31) 34 (56) 2. 8 1. 2-6. 4
Combined ORs 2. 5 1. 8-3. 3
HC, historical control (non-hypothermia) group; TH, therapeutic hypothermia group; OR, odds ratio; CI, confidence interval.
aAll percentages rounded to nearest integer.
THERAPEUTIC HyPOTHERMIA
141
 
TABLE 3. Survival and favorable outcome in studies without 
historical controls36
Author TH, n
Survival,  
n (%)α
Favorable 
Neurologic 
Outcome,  
n (%)
Al-Senani et al43  13  9 (69)  5 (38)
Feuchtl et al44  19  11 (58)  9 (47)
Haugk et al45 28  14 (50)  9 (32)
Hovdenes et al46 50  41 (82)  34 (68)
Kliegel et al47 26  14 (54)  13 (50)
Laish-Farkash et al48 51  32 (63)  31 (61)
Scott et al49 49  19 (39)  16 (33)
TH, therapeutic hypothermia.
aAll percentages rounded to nearest integer.
Favorable neurologic outcome is defined as Cerebral Performance 
Category at discharge of 1 or 2.
TABLE 2. Favorable outcomes in study subset with historical controls36
Author
n Historical control  
n (%)α
Therapeutic Hypothermia  
n (%) OR 95% CI HC TH
Arrich et al37  123 462 39 (32) 212 (46) 1. 8 1. 2-2. 8
Belliard et al38  36 32 6 (17) 13 (41) 3. 4 0. 99-12. 8
Busch et al39  34 27 9 (26) 11 (41) 1. 9 0. 6-6. 5
Oddo et al40  54 55 11 (20) 26 (47) 3. 5 1. 4-9. 1
Schefold et al41  31 31 6 (19) 19 (61) 6. 6 2. 1-20. 8
Sunde et al42  58 61 15 (26) 34 (56) 3. 6 1. 6-8. 5
Combined ORs 2. 5 1. 9-3. 4
HC, historical control (non-hypothermia) group; TH, therapeutic hypothermia group; OR, odds ratio; CI, confidence interval.
aAll percentages rounded to nearest integer.
Favorable outcome is defined as Cerebral Performance Category at discharge of 1 or 2.
ies without historical controls was 45%, again similar to the 
47% of the controlled studies cited in Table 1.
N O N - v F  A R R E S T
Patients with an initial cardiac rhythm of asystole have 
a lower rate of survival than patients with VF, presumably 
because the longer period of cardiac arrest has caused VF 
to degenerate into asystole.18 This longer cardiac arrest time 
would lead to a more severe neurological injury. Given this 
increased severity of neurological injury, the possible role of 
therapeutic hypothermia after non-VF arrest remains uncer-
tain. There have been three clinical studies that provide data 
relevant to this patient group. In a pilot trial, Hachimi-Idrissi 
et al randomized 30 comatose patients to either therapeutic 
hypothermia or normothermia after non-VF arrest.50 Hy-
pothermia was induced with local surface cooling and was 
maintained for 4 hours. In the hypothermia group of 16 pa-
tients, 2 patients (13%) survived with favorable neurological 
recovery as compared to 0 of 14 (0%) in the normothermia 
group. This difference was not statistically significant. In a 
prehospital study, Kim et al,51 randomized patients with out-
of-hospital cardiac arrest to either paramedic cooling using a 
rapid intravenous bolus of 2 L of ice-cold saline or normoth-
ermia. Of 125 resuscitated patients, 74 had an initial cardiac 
rhythm of asystole or pulseless electrical activity (PEA). In 
the therapeutic hypothermia group, three of 34 patients (9%) 
recovered as compared to nine of 40 patients (23%) assigned 
to normothermia. In this study, numbers were also too small 
to draw any conclusion concerning the efficacy of therapeutic 
hypothermia.
In a third study, the results of the implementation of a 
protocol for therapeutic hypothermia in a Scottish hospital 
were reported.52 There were 139 out-of-hospital cardiac arrest 
patients admitted over a 4-year period. Of these, 27% had a 
favorable outcome (discharged home or to rehabilitation). Of 
the favorable outcome patients, 41% were VF patients and only 
7% were non-VF patients. Given such low rates of recovery 
after non-VF arrest (approximately 7%–12%), a prospective 
study comparing therapeutic hypothermia to normothermia 
in non-VF patients would require a very large number of pa-
tients to show any potentially improved outcomes. Therefore, 
in patients with anoxic brain injury after non-VF cardiac 
arrest, clinicians will need to balance the possible benefit of 
therapeutic hypothermia against the possible side effects of 
this therapy. However, the latter may be easily managed in 
the critical care setting.
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PA T I E N T S  w I T H  S H O C K  F O L L O w I N G  C A R d I A C 
A R R E S T  R E S U S C I T A T I O N
Patients resuscitated from cardiac arrest often have hemo-
dynamic instability due to the myocardial dysfunction that is 
present for some hours to days.53 These data also suggest that 
therapeutic hypothermia may be successfully implemented 
when the post–cardiac arrest patient presents with cardiogenic 
shock, together with other standard therapeutic measures in 
this setting such as urgent coronary artery catheterization. 
However, there is currently insufficient data to confirm that 
this approach improves outcomes. Knafelj et al,54 compared 
40 patients with ST-segment elevation myocardial infarction 
(STEMI) undergoing percutaneous coronary intervention 
(PCI) with cooling after cardiac arrest to 32 patients undergo-
ing PCI without cooling. Cooling was started before, during, 
or after PCI. Neurological outcome was better in the cooling 
group (55% favorable outcome vs only 16% of the non-cooling 
group; P=0.01), and the combination of therapeutic hypo-
thermia and PCI proved to be safe and feasible.
 
While most 
of the patients in this study were cooled after PCI,54 Wolfrum 
et al,55 induced hypothermia in 16 patients with STEMI after 
successful resuscitation but before PCI and compared them 
to 17 historical controls. The combination treatment proved 
to be safe and feasible and did not increase the “door-to- bal-
loon” time. In another study,40 five of 17 hypothermia-treated 
patients with postresuscitation shock survived with good 
neurological recovery, while all 14 normothermic controls 
died (P=0.027).
I N - H O S P I T A L  C A R d I A C  A R R E S T
In-hospital cardiac arrest generally has a different etiology 
compared with out-of-hospital cardiac arrest.6,56,57 Whereas 
most out-of hospital cardiac arrest is due to underlying cardiac 
disease, in-hospital cardiac arrest (outside the emergency 
room or critical care unit) is generally due to causes such as 
respiratory failure, pulmonary embolism, electrolyte abnor-
malities, and/or severe sepsis.6,56,57 In addition, after the cardiac 
arrest is recognized and the “blue code” called, cardiopulmo-
nary resuscitation is undertaken and a medical team which 
provides advanced life support care arrives within less than 
3-5 minutes.6,57 Nevertheless, despite the rapid response, sig-
nificant neurological injury may occur after resuscitation from 
in-hospital cardiac arrest. For example, in an observational 
study from the USA National Registry of Cardiopulmonary 
Resuscitation, there were 36,902 patients with in-hospital 
cardiac arrest and the rate of survival to hospital discharge 
was 18%.57 Of the survivors, 27% had poor neurological out-
come, presumably due to the anoxic neurological injury from 
prolonged, unrecognized cardiac arrest that occurred in a 
non-monitored area before recognition of cardiac arrest from 
the hospital staff. Our results on good neurological recovery 
rate were similar.6 Given the feasibility and few side effects 
of therapeutic hypothermia, it would seem reasonable to sys-
tematically implement it following ROSC. In fact, in cases of 
prolonged cardiopulmonary resuscitation, consideration could 
be given to induction of hypothermia even before ROSC.
H y P O T H E R M I A  I N  B R A I N  I N j U R y  A N d  S T R O K E
Several studies suggest that hypothermia or even control-
led normothermia reduces brain edema and intracranial pres-
sure in patients with traumatic brain injury.58,59 By contrast, 
only a few small pilot studies have evaluated hypothermia 
as a treatment for acute ischemic stroke, and no controlled 
trials of hypothermia for hemorrhagic stroke have been per-
formed.60 Despite the fact that more outcome data are needed 
to recommend hypothermia for standard practice, there is a 
strong physiological rationale and ample experimental data 
supporting its use. The multiple neuroprotective mechanisms 
of hypothermia are summarized in Table 4.
S I d E  E F F E C T S  O F  H y P O T H E R M I A
The possible side effects include shivering, changes in 
the immune system, electrolyte disturbances, coagulation 
abnormalities, cardiovascular side effects, alterations of 
drug metabolism. Shivering could counteract the beneficial 
effects of hypothermia by raising energy and oxygen demands. 
Therefore, muscle paralysis was used in the randomized con-
trolled trials.25,26
 
The detection of infections might be delayed 
because fever as an indicator of infection is suppressed by the 
hypothermia. Minor electrolyte changes that can be expected 
include hypernatremia, hypokalemia, hypomagnesemia, hy-
pophosphatemia, and hypocalcemia. Hypothermia leads to 
bradycardia and a rise in systemic vascular resistance. The risk 
of arrhythmias (bradycardia necessitating pacemaker support, 
atrial fibrillation, or VF) rises with temperatures below 30°C 
but is very low at 33°C. Serious complications have not been 
TABLE 4. Mechanisms of action by which hypothermia can 
limit ischemic damage.60
Reduced metabolic demand
Reduced proteolysis
Cell membrane stabilization
Inhibits spreading depolarizations
Decreased excitotoxic damage
Reduces lactate and tissue acidosis
Reduced free radical and reactive oxygen species formation
Alters apoptotic signals
Reduction in neuronal calcium influx and toxicity
Reduces ischemia-associated gene expression
Inhibits inflammation and cytokine production
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observed to a significant extent in the major randomized trials. 
25,26
 
Sagalyn et al36 analyzed the reported adverse events and a 
relevant summary is provided in Table 5.
A limitation of the current literature is that the severity 
of the adverse events is rarely reported although it is of great 
relevance to practitioners; for example, in the study by Arrich 
et al,37 3% of therapeutic hypothermia patients had bleeding 
complications, but only 1% required treatment. Future stud-
ies will hopefully present more data on the adverse effects of 
hypothermia, and perhaps, on their effect on outcome. This 
might then result in the specification of (any) contraindica-
tions to hypothermia.
C O N C L U S I O N
Therapeutic hypothermia is a safe and effective therapy 
after cardiac arrest and is recommended by the American 
Heart Association and the International Liaison Committee 
on Resuscitation for unconscious adult patients with sponta-
neous circulation after out-of-hospital VF cardiac arrest. It 
should also be considered for out-of-hospital cardiac arrest 
from a non-shockable rhythm or cardiac arrest in hospital. 
It is so far the only therapy that improved neurological out-
come after cardiac arrest in randomized controlled trials. 
Hypothermia can be induced safely in hemodynamically 
compromised patients as well as in patients undergoing PCI. 
New technology for both surface and intravascular cooling has 
been developed that enables more rapid cooling and accurate 
temperature control. Future studies should provide more data 
on the adverse effects of therapeutic hypothermia, in order to 
improve the safety of the hypothermia protocols.
TABLE 5. Overview of adverse events36
Author Group n
Pneumonia
(%)α
Sepsis
(%)
Arrhythmia
(%)
Bleeding
(%)
Arrich et al37 TH 462 NR NR 28 (6) 15 (3)
Busch et al39 TH 27 19 (70) NR 7 (26) NR
Busch et al39 HC 26 13 (50) NR 9 (35) NR
Laish-Farkash et al48 TH 51 27 (53) 12 (24) 5 (10) 8 (16)
Oddo et al40 TH 55 16 (29) 2 (4) 20 (36) NR
Oddo et al40 HC 54 19 (35) 2 (4) 23 (43) NR
Sunde et al42 TH 61 29 (47) 2 (8) 15 (25) 5 (8)
Sunde et al42 HC 58 33 (57) 1 (2) 9 (16) NR
Total, TH TH 656 91/194 (47) 16/167 (10) 75/656 (11) 28/574 (5)
Total, HC HC 138 65/138 (47) 3/112 (3) 41/138 (30) NA
TH, therapeutic hypothermia group; HC, historical control (non-hypothermia) group;
NR, not reported; NA, not applicable.
a, All percentages rounded to nearest integer.
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